NASDAQ:SONN Sonnet BioTherapeutics (SONN) Stock Price, News & Analysis → Elon Musk’s Final Masterpiece: “X-9840” (From Paradigm Press) (Ad) Free SONN Stock Alerts $1.70 +0.06 (+3.66%) (As of 06/7/2024 ET) Add Compare Share Share Today's Range$1.64▼$1.7550-Day Range$1.50▼$2.0252-Week Range$1.08▼$26.40Volume21,044 shsAverage Volume69,749 shsMarket Capitalization$5.29 millionP/E RatioN/ADividend YieldN/APrice Target$30.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Sonnet BioTherapeutics alerts: Email Address Sonnet BioTherapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,664.7% Upside$30.00 Price TargetShort InterestBearish14.48% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.58Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($2.14) to ($2.52) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.59 out of 5 stars 3.5 Analyst's Opinion Consensus RatingSonnet BioTherapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageSonnet BioTherapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Sonnet BioTherapeutics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted14.48% of the float of Sonnet BioTherapeutics has been sold short.Short Interest Ratio / Days to CoverSonnet BioTherapeutics has a short interest ratio ("days to cover") of 4.2.Change versus previous monthShort interest in Sonnet BioTherapeutics has recently increased by 2.05%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldSonnet BioTherapeutics does not currently pay a dividend.Dividend GrowthSonnet BioTherapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SONN. Previous Next 2.0 News and Social Media Coverage News SentimentSonnet BioTherapeutics has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Sonnet BioTherapeutics this week, compared to 1 article on an average week. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Sonnet BioTherapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.00% of the stock of Sonnet BioTherapeutics is held by insiders.Percentage Held by InstitutionsOnly 9.45% of the stock of Sonnet BioTherapeutics is held by institutions.Read more about Sonnet BioTherapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Sonnet BioTherapeutics are expected to decrease in the coming year, from ($2.14) to ($2.52) per share.Read more about Sonnet BioTherapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Market Moving TrendsTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Click to View The 5 Best AI Stocks to Invest In About Sonnet BioTherapeutics Stock (NASDAQ:SONN)Sonnet BioTherapeutics Holdings, Inc., a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead product candidate is SON-1010, a fully human single-chain version of interleukin 12 that is in Phase 1b/2a clinical trial for the treatment of solid tumor indications, including ovarian cancer, non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6, which is in Phase 1b/I2a clinical trail to treat chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy; and SON-1210, a bispecific compound for solid tumor indications, including colorectal cancer. It has a license agreement with New Life Therapeutics Pte, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin-6. The company is headquartered in Princeton, New Jersey.Read More SONN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SONN Stock News HeadlinesJune 4, 2024 | americanbankingnews.comSonnet BioTherapeutics (NASDAQ:SONN) versus Salarius Pharmaceuticals (NASDAQ:SLRX) Critical SurveyJune 1, 2024 | americanbankingnews.comFY2024 EPS Estimates for Sonnet BioTherapeutics Holdings, Inc. Increased by Chardan Capital (NASDAQ:SONN)May 29, 2024 | americanbankingnews.comSonnet BioTherapeutics' (SONN) "Buy" Rating Reaffirmed at Chardan CapitalMay 28, 2024 | globenewswire.comSonnet BioTherapeutics to Present SB221 as a Trial in Progress at the ASCO 2024 Annual MeetingMay 22, 2024 | finanznachrichten.deSonnet BioTherapeutics, Inc.: Sonnet BioTherapeutics Announces Review of Strategic AlternativesMay 22, 2024 | finance.yahoo.comSonnet BioTherapeutics Announces Review of Strategic AlternativesMay 15, 2024 | investorplace.comSONN Stock Earnings: Sonnet BioTherapeutics Misses EPS for Q2 2024April 28, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Cullinan Management (CGEM) and HCA Healthcare (HCA)April 17, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Legend Biotech (LEGN), Genmab (GMAB)April 12, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Bausch Health Companies (BHC) and Arcus Biosciences (RCUS)March 11, 2024 | finance.yahoo.comSonnet BioTherapeutics Announces Early Safety Data from the Company’s Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Met the Study’s Initial Pre-Specified ObjectiveMarch 1, 2024 | morningstar.comSonnet BioTherapeutics Holdings Inc Ordinary Shares SONNFebruary 29, 2024 | finanznachrichten.deSonnet BioTherapeutics, Inc.: Sonnet BioTherapeutics Announces a Publication Demonstrating Safety and Tolerability of SON-1010 in Healthy VolunteersFebruary 29, 2024 | msn.comSonnet BioTherapeutics Reported SON-1010 Phase I Trial Results: Demonstrates Safety, Efficacy in Melanoma Model, and Potential for Dose EscalationFebruary 17, 2024 | finance.yahoo.comSonnet BioTherapeutics Holdings First Quarter 2024 Earnings: Beats ExpectationsFebruary 14, 2024 | finance.yahoo.comSonnet BioTherapeutics Provides Fiscal Year 2024 First Quarter Business and Earnings UpdateFebruary 7, 2024 | msn.comNasdaq panel expected to decide on Yield10 listing within next monthJanuary 1, 2024 | markets.businessinsider.comBTIG Keeps Their Buy Rating on Sonnet BioTherapeutics Holdings (SONN)December 22, 2023 | msn.comSonnet BioTherapeutics files for $100M mixed shelfDecember 21, 2023 | finance.yahoo.comSonnet BioTherapeutics Announces Publication Demonstrating Suitability of SON-1210, the First Albumin-binding Bifunctional IL-12/IL-15 Fusion Protein, for Solid Tumor ImmunotherapyDecember 16, 2023 | markets.businessinsider.comBuy Rating Affirmed for Sonnet BioTherapeutics Amid Promising Oncology Trials and Financial FortitudeDecember 14, 2023 | finance.yahoo.comSonnet BioTherapeutics Provides Fiscal Year 2023 Business and Financial UpdateOctober 31, 2023 | finance.yahoo.comSonnet BioTherapeutics Provides Fiscal Year 2023 Business OverviewOctober 26, 2023 | benzinga.comWhat's Happening With Sonnet BioTherapeutics (SONN) Shares?October 25, 2023 | markets.businessinsider.comDow Falls Over 100 Points; Alphabet Shares Tumble After Q3 ResultsSee More Headlines Receive SONN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sonnet BioTherapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/14/2024Today6/07/2024Next Earnings (Estimated)8/12/2024Fiscal Year End9/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:SONN CUSIPN/A CIK1106838 Webwww.chanticleerholdings.com Phone609-375-2227Fax704-366-2463Employees12Year FoundedN/APrice Target and Rating Average Stock Price Target$30.00 High Stock Price Target$30.00 Low Stock Price Target$30.00 Potential Upside/Downside+1,664.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-18,830,000.00 Net Margins-11,187.19% Pretax Margin-9,037.59% Return on Equity-382.31% Return on Assets-126.21% Debt Debt-to-Equity RatioN/A Current Ratio1.89 Quick Ratio1.89 Sales & Book Value Annual Sales$150,000.00 Price / Sales35.25 Cash FlowN/A Price / Cash FlowN/A Book Value($0.13) per share Price / Book-13.08Miscellaneous Outstanding Shares3,110,000Free Float3,050,000Market Cap$5.29 million OptionableNot Optionable Beta0.58 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesDr. Pankaj Mohan Ph.D. (Age 59)Founder, Chairman, CEO & President Comp: $927kDr. John K. Cini Ph.D. (Age 71)Chief Scientific Officer & Co-Founder Comp: $602.48kMr. Jay Cross (Age 54)Chief Financial Officer Comp: $603.42kMr. Donald J. Griffith CPA (Age 75)CPA, Controller & Director Comp: $134.05kMs. Susan Dexter (Age 69)Chief Technical Officer Dr. Richard T. Kenney FACP (Age 66)M.D., Chief Medical Officer Mr. Manuel DafonsecaHead of Clinical OperationsMore ExecutivesKey CompetitorsNeuroBo PharmaceuticalsNASDAQ:NRBOKALA BIONASDAQ:KALAJaguar HealthNASDAQ:JAGXGlycoMimeticsNASDAQ:GLYCVincerx PharmaNASDAQ:VINCView All CompetitorsInsidersSusan DexterBought 454 shares on 6/14/2023Total: $6,991.60 ($15.40/share)View All Insider Transactions SONN Stock Analysis - Frequently Asked Questions Should I buy or sell Sonnet BioTherapeutics stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Sonnet BioTherapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SONN shares. View SONN analyst ratings or view top-rated stocks. What is Sonnet BioTherapeutics' stock price target for 2024? 2 brokers have issued 12 month price targets for Sonnet BioTherapeutics' stock. Their SONN share price targets range from $30.00 to $30.00. On average, they anticipate the company's share price to reach $30.00 in the next year. This suggests a possible upside of 1,664.7% from the stock's current price. View analysts price targets for SONN or view top-rated stocks among Wall Street analysts. How have SONN shares performed in 2024? Sonnet BioTherapeutics' stock was trading at $1.74 on January 1st, 2024. Since then, SONN stock has decreased by 2.3% and is now trading at $1.70. View the best growth stocks for 2024 here. When is Sonnet BioTherapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 12th 2024. View our SONN earnings forecast. How were Sonnet BioTherapeutics' earnings last quarter? Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) issued its quarterly earnings results on Tuesday, May, 14th. The company reported $0.07 EPS for the quarter. Sonnet BioTherapeutics had a negative net margin of 11,187.19% and a negative trailing twelve-month return on equity of 382.31%. When did Sonnet BioTherapeutics' stock split? Sonnet BioTherapeutics's stock reverse split before market open on Friday, September 1st 2023. The 1-22 reverse split was announced on Friday, September 1st 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, September 1st 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of Sonnet BioTherapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Sonnet BioTherapeutics investors own include Gevo (GEVO), Sorrento Therapeutics (SRNE), Boxlight (BOXL), T2 Biosystems (TTOO), Biocept (BIOC), iBio (IBIO), Trevena (TRVN), Vaxart (VXRT), ADMA Biologics (ADMA) and Advanced Micro Devices (AMD). How do I buy shares of Sonnet BioTherapeutics? Shares of SONN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:SONN) was last updated on 6/8/2024 by MarketBeat.com Staff From Our PartnersMillionaire-Making “Wealth Pattern” Just Repeated on April 22If you think you missed out on the Bitcoin band wagon… You need to watch this immediately.Paradigm Press | SponsoredBreaking - The US Gov. Seized CITGODo you want an investment that can double or triple your money in the next three months? The US Court is cu...Augury Research | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredAI Hell Will Break Loose [June 30, 2024] …On June 30, 2024, AI will reach a critical tipping point… Whatever you do, make sure you prepare before Ju...Banyan Hill Publishing | SponsoredWas the Great Financial Crisis fun?The Great Financial Crisis, which actually started in the summer of 2007 and did not end until March of 2009, ...Brooks Enterprises | SponsoredCollapse of the Petrodollar The death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sonnet BioTherapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sonnet BioTherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.